MP45-07 PATHOLOGICAL OUTCOMES IN MEN WITH LOW RISK PROSTATE CANCER DIAGNOSED ON INITIAL VERSUS REPEAT TRANSRECTAL ULTRASOUND PROSTATE BIOPSY

Ahmed Elshafei,Yonghong Li,Ganesh Kartha,Asmaa Hatem,Anthony Avallone,Eric Klein,J. Stephen Jones

DOI: https://doi.org/10.1016/j.juro.2014.02.1204

IF: 7.6

2014-01-01

The Journal of Urology

Abstract:You have accessJournal of UrologyProstate Cancer: Localized III1 Apr 2014MP45-07 PATHOLOGICAL OUTCOMES IN MEN WITH LOW RISK PROSTATE CANCER DIAGNOSED ON INITIAL VERSUS REPEAT TRANSRECTAL ULTRASOUND PROSTATE BIOPSY Ahmed Elshafei, Yonghong Li, Ganesh Kartha, Asmaa Hatem, Anthony Avallone, Eric Klein, and J.Stephen Jones Ahmed ElshafeiAhmed Elshafei More articles by this author , Yonghong LiYonghong Li More articles by this author , Ganesh KarthaGanesh Kartha More articles by this author , Asmaa HatemAsmaa Hatem More articles by this author , Anthony AvalloneAnthony Avallone More articles by this author , Eric KleinEric Klein More articles by this author , and J.Stephen JonesJ.Stephen Jones More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.1204AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail Introduction and Objectives To assess the pathological outcomes after radical prostatectomy (RP) in men with low risk (LR) prostate cancer (PCa) diagnosed on initial vs. repeat transrectal ultrasound guided biopsy. Methods From our IRB approved database, we identified 544 patients eligible for active surveillance (AS) with clinical criteria of LR PCa (defined by National Comprehensive Cancer Network as stage T1c/T2a, prostate specific antigen ≤10 ng/ml and Gleason score ≤6) who underwent RP at our institution. Patients were divided into two groups; 1.) 375 men diagnosed with PCa on initial biopsy and 2.) 169 men diagnosed on repeat biopsy. We compared adverse oncological outcomes defined as Gleason upgrading (score≥ 7), extraprostatic extension (EPE), seminal vesicle invasion (SV) and a positive surgical margin. Results There was no significant difference in the clinico-demographic characteristics between patients diagnosed with PCa on initial biopsy and those diagnosed on repeat biopsy. Patients diagnosed with PCa on repeat biopsy showed lower disease volume (lower median number of positive cores P=0.002, and lower maximum cancer % involved per core, P<.0001). There was no significant difference regarding Gleason sum and total prostate volume at the time of positive biopsy (Table 1). Gleason upgrade after RP was significantly higher in patients diagnosed on initial biopsy compared to repeat biopsy (58.7% vs. 41.8%, P=0.0003). In addition, EPE was higher in patients with PCa on initial biopsy (13.9% vs. 7.3%, P=0.03). Table 2. Conclusions The likelihood of adverse oncological outcomes at time of RP among patients diagnosed with low risk PCa on initial vs. repeat biopsy provides important clinical guidance for selection of men eligible for AS. Patients diagnosed with low risk PCa on repeat biopsy usually harbor lower disease volume and are less likely to have EPE or Gleason upgrading compared to those diagnosed on initial biopsy. This has implications for patients considering active surveillance based solely on a single diagnostic biopsy. Table 1. Descriptive statistics of the study population and univariate comparisons Variables Patients with cancer on initial biopsy (N =375 ), Median (IQR),/Count (%) Patients with cancer on repeat biopsy (N =169 ), Median (IQR),/Count (%) p-value Age 58.86 (54.8-63) 59.8 (55.6-63.7) 0.23 African American race 54/373 (14.5%) 19/167 (11.38%) 0.33 Family History of PCa 92/375 (24.5%) 41/167 (24.5%) 0.99 PSA 4.77 (3.9-6.1) 5.1 (3.84-6.57) 0.17 PSAD 0.12 (0.09-0.16) 0.12 (0.09-0.18) 0.77 %Free PSA 15.5 (11-20) 15 (11-19) 0.76 Clinical Stage 0.16 T1c 326/375 (86.9%) 154/169 (91.1%) T2A 49/375 (13.1%) 15/169 (8.9%) Maximum cancer % 15 (5-40) 10 (5-25) <.0001 No. of positive cores 2 (1-3) 1 (1-2.5) 0.002 Biopsy Gleason sum 6 (6-6) 6 (6-6) 0.6 Total prostate volume 40 ( 28-51) 40 (29.9-56) 0.22 Table 2. Adverse oncological outcomes in radical prostatectomy Patients with cancer on initial biopsy (n=375) Patients with cancer on repeat biopsy (n=169) P-value Gleason upgrade ( ≥7) 215/366 (58.7%) 69/165 (41.8%) 0.0003 Extra prostatic extension 51/366 (13.93%) 12/164 (7.32%) 0.03 Seminal vesicle involvement 0/372 (0%) 1/166 (0.6%) 0.6 Positive surgical margin 73/373 (19.6%) 23/167 (13.8%) 0.1 © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e461-e462 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Ahmed Elshafei More articles by this author Yonghong Li More articles by this author Ganesh Kartha More articles by this author Asmaa Hatem More articles by this author Anthony Avallone More articles by this author Eric Klein More articles by this author J.Stephen Jones More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...